October 18, 2018

West Lafayette-Based Endocyte Aquired For $2.1 Billion By Pharma Giant Novartis

Article origination IPBS-RJC
West Lafayette-Based Endocyte Aquired For $2.1 Billion By Pharma Giant Novartis

West Lafayette-Based Endocyte Aquired For $2.1 Billion By Pharma Giant Novartis

Swiss pharmaceutical giant Novartis says it will acquire West Lafayette-based Endocyte for $2.1 billion.

Endocyte was founded in Purdue Research Park and has been working for more than two decades to develop personalized cancer treatments that are more targeted to a specific patient’s cancer than traditional, broad-spectrum radiation therapy.

In the company’s press release, Endocyte president and CEO Mike Sherman says the acquisition will allow for a prostate cancer drug that’s now in late-stage clinical trials to have what he calls better "global reach" with Novartis’s expertise.

Earlier this month, Endocyte was the first Purdue startup to reach $1.5 billion in valuation.

Company executives did not respond to a request for comment.

Support independent journalism today. You rely on WFYI to stay informed, and we depend on you to make our work possible. Donate to power our nonprofit reporting today. Give now.

 

 

Related News

IDOH launches resource to connect Hoosiers to monoclonal antibody treatment for COVID-19
Indiana’s public health commission explores funding issues that health officials say exacerbate disparities
Indiana has a chance to help more kids with lead poisoning than ever before